Impact of the mutation profile on thrombotic risk in cancer patients

Abstract

Patients with cancer present with an elevated risk of thrombosis, which entails high morbidity and mortality. Various predictive scales that incorporate clinical and biological data have been developed to identify those at high risk of thrombosis, but, in general, they do not allow for the optimal selection of subjects who are candidates for thromboprophylaxis.

Recent studies have demonstrated that the mutation profile has a high impact on the risk of thrombosis; this will facilitate developing new predictive models of thrombosis in patients with cancer.

CITATION  Rev Clin Esp (Barc). 2022 Feb;222(2):93-99.  doi: 10.1016/j.rceng.2021.04.008. Epub 2021 Sep 20.